Table 4. Multivariable analyses for 2-year TB risk in bDMARDs users.
| Univariable | Multivariable | |||||
|---|---|---|---|---|---|---|
| HR | 95%CI | P-value | HR | 95%CI | P-value | |
| Age | ||||||
| <65 year of age | Reference | Reference | Reference | Reference | ||
| ≥65 year of age | 3.24 | 1.46–7.23 | 0.004 | 2.72 | 1.06–6.99 | 0.037 |
| Sex | ||||||
| Women | Reference | Reference | ||||
| Men | 0.90 | 0.41–1.97 | 0.791 | |||
| Disease duration | ||||||
| ≥4 years | Reference | Reference | ||||
| <4 years | 1.20 | 0.50–2.84 | 0.683 | |||
| TB history | 5.31 | 1.60–17.63 | 0.006 | 6.24 | 1.77–22.00 | 0.004 |
| Latent TB | 1.66 | 0.73–3.79 | 0.229 | |||
| bDMARDs | ||||||
| Etanercept | Reference | Reference | ||||
| Adalimumab | 1.41 | 0.66–3.02 | 0.371 | |||
| Golimumab | - | - | - | |||
| Tocilizumab | - | - | - | |||
| Abatacept | - | - | - | |||
| Tofacitinib | - | - | - | |||
| Diabetes mellitus | 2.98 | 0.71–12.57 | 0.138 | |||
| CVD | 1.20 | 0.16–8.81 | 0.861 | |||
| CKD | 1.81 | 0.43–7.66 | 0.418 | |||
| Hepatitis | 1.22 | 0.37–4.05 | 0.749 | |||
| Anemia | 2.01 | 0.87–4.65 | 0.105 | |||
| Concomitant medications | ||||||
| Methotrexate | 1.88 | 0.82–4.30 | 0.133 | |||
| Leflunomide | 0.74 | 0.22–2.44 | 0.616 | |||
| Sulfasalazine | 0.26 | 0.09–0.75 | 0.013 | 0.32 | 0.11–0.97 | 0.043 |
| Hydroxychloroquine | 0.58 | 0.25–1.37 | 0.215 | |||
| Ciclosporine | 1.37 | 0.48–3.97 | 0.558 | |||
| Corticosteroid | ||||||
| <5mg | Reference | Reference | Reference | Reference | ||
| ≥5mg | 5.02 | 1.47–17.16 | 0.010 | 5.01 | 1.46–17.21 | 0.010 |
| Initiation of bDMARDs/tDMARDs | ||||||
| Before 2012 | Reference | Reference | ||||
| After 2012 | 0.67 | 0.30–1.49 | 0.323 | |||
Abrreviations: OR, odds ratio, TB, tuberculosis; bDMARDS, biological drug modifying anti-rheumatic drugs; tDMARDs, targeted disease modifying anti-rheumatic drugs; CVD, cardiovascular disease; CKD, chronic kidney disease